Publications by authors named "Patrick Jaynes"

DNA replication stress (RS) is a widespread phenomenon in carcinogenesis, causing genomic instability and extensive chromatin alterations. DNA damage leads to activation of innate immune signaling, but little is known about transcriptional regulators mediating such signaling upon RS. Using a chemical screen, we identified protein arginine methyltransferase 5 (PRMT5) as a key mediator of RS-dependent induction of interferon-stimulated genes (ISGs).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the distinct regions of the germinal center (GC)—the dark zone (DZ) and light zone (LZ)—which are crucial for B-cell expansion and antibody maturation, yet lack a clear understanding of their immune composition differences.
  • Researchers discovered specific DNA damage responses and chromatin features that explain why T-cells are excluded from the DZ region, providing insights into its immune-repulsive characteristics.
  • The findings highlight the role of the ATR kinase in regulating responses in the DZ, suggesting that targeting ATR could enhance immunotherapy effectiveness for aggressive types of lymphoma like Diffuse Large B-cell Lymphomas (DLBCL).
View Article and Find Full Text PDF

Macrophages are abundant immune cells in the microenvironment of diffuse large B-cell lymphoma (DLBCL). Macrophage estimation by immunohistochemistry shows varying prognostic significance across studies in DLBCL, and does not provide a comprehensive analysis of macrophage subtypes. Here, using digital spatial profiling with whole transcriptome analysis of CD68+ cells, we characterize macrophages in distinct spatial niches of reactive lymphoid tissues (RLTs) and DLBCL.

View Article and Find Full Text PDF

Deregulation of the DNA damage response (DDR) plays a critical role in the pathogenesis and progression of many cancers. The dependency of certain cancers on DDR pathways has enabled exploitation of such through synthetically lethal relationships e.g.

View Article and Find Full Text PDF

Unlabelled: Cancers often overexpress multiple clinically relevant oncogenes, but it is not known if combinations of oncogenes in cellular subpopulations within a cancer influence clinical outcomes. Using quantitative multispectral imaging of the prognostically relevant oncogenes MYC, BCL2, and BCL6 in diffuse large B-cell lymphoma (DLBCL), we show that the percentage of cells with a unique combination MYC+BCL2+BCL6- (M+2+6-) consistently predicts survival across four independent cohorts (n = 449), an effect not observed with other combinations including M+2+6+. We show that the M+2+6- percentage can be mathematically derived from quantitative measurements of the individual oncogenes and correlates with survival in IHC (n = 316) and gene expression (n = 2,521) datasets.

View Article and Find Full Text PDF
Article Synopsis
  • Combination therapy is currently the standard treatment for relapsed/refractory non-Hodgkin's lymphoma (RR-NHL), but response rates are often low, especially in patients resistant to chemotherapy.
  • Researchers evaluated a new method called quadratic phenotypic optimization platform (QPOP), which can predict effective drug combinations using limited tumor samples from RR-NHL patients.
  • In a study involving 71 patients, QPOP-guided treatments showed improved outcomes and fewer cases of disease progression compared to traditional chemotherapy, providing a strong basis for future clinical trials on this approach.
View Article and Find Full Text PDF
Article Synopsis
  • PLK1 inhibitors show promise in treating certain hard-to-treat cancers, but not all patients with PLK1 overexpression respond to these drugs due to the absence of reliable patient selection markers.
  • Research found that cancer cells lacking the ARID1A tumor suppressor gene are particularly sensitive to PLK1 inhibition, not due to its usual role in cell cycle regulation, but linked to issues in their mitochondrial functions.
  • The study reveals a novel role for PLK1 in supporting mitochondrial health, especially under stress, and proposes a method for identifying patients who may benefit from PLK1 inhibitors based on ARID1A protein levels.
View Article and Find Full Text PDF

B-cell receptor (BCR) signalling is critical for the survival of B-cell lymphomas and is a therapeutic target of drugs such as Ibrutinib. However, the role of T-cell receptor (TCR) signalling in the survival of T/Natural Killer (NK) lymphomas is not clear. ZAP-70 (zeta associated protein-70) is a cytoplasmic tyrosine kinase with a critical role in T-cell receptor (TCR) signalling.

View Article and Find Full Text PDF

Early relapse after platinum chemotherapy in epithelial ovarian cancer (EOC) portends poor survival. A-priori identification of platinum resistance is therefore crucial to improve on standard first-line carboplatin-paclitaxel treatment. The DNA repair pathway homologous recombination (HR) repairs platinum-induced damage, and the HR recombinase RAD51 is overexpressed in cancer.

View Article and Find Full Text PDF
Article Synopsis
  • The PI3K pathway is identified as a potential target for melanoma therapy, showcasing significant genetic diversity among the early passage cell lines derived from metastatic melanomas.
  • A majority of these cell lines exhibited upregulation of the PI3K pathway through various mechanisms, including genetic alterations in key PI3K components like PIK3CA and regulatory subunits.
  • Inhibitors targeting the PI3K pathway showed variable effectiveness, with mTOR-selective or dual inhibitors proving to be effective against all tested lines, including those resistant to other treatments.
View Article and Find Full Text PDF

Systematic control of the transforming growth factor-β (TGFβ) pathway is essential to keep the amplitude and the intensity of downstream signalling at appropriate levels. Ubiquitination plays a crucial role in the general regulation of this pathway. Here we identify the deubiquitinating enzyme OTUD4 as a transcriptional target of the TGFβ pathway that functions through a positive feedback loop to enhance overall TGFβ activity.

View Article and Find Full Text PDF

Treatment of muscle-invasive bladder cancer remains a major clinical challenge. Aberrant HGF/c-MET upregulation and activation is frequently observed in bladder cancer correlating with cancer progression and invasion. However, the mechanisms underlying HGF/c-MET-mediated invasion in bladder cancer remains unknown.

View Article and Find Full Text PDF
Article Synopsis
  • USP15 is a deubiquitinase that influences various important biological processes and is linked to several diseases.
  • Researchers created specific ubiquitin variants (UbVs) targeting different domains of USP15, including a more effective linear dimer (diUbV) that inhibits USP15’s activity better than single UbVs.
  • These UbVs successfully inhibited the deubiquitination of key substrates and altered USP15's effects on important signaling pathways, paving the way for further research into its role in various health areas like cancer and inflammation.
View Article and Find Full Text PDF

RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated through the loss of negative feedback loops after MAPK inhibition and reactivation of upstream signaling.

View Article and Find Full Text PDF

The initial experiments performed by Rose, Hershko, and Ciechanover describing the identification of a specific degradation signal in short-lived proteins paved the way to the discovery of the ubiquitin mediated regulation of numerous physiological functions required for cellular homeostasis. Since their discovery of ubiquitin and ubiquitin function over 30years ago it has become wholly apparent that ubiquitin and their respective ubiquitin modifying enzymes are key players in tumorigenesis. The human genome encodes approximately 600 putative E3 ligases and 80 deubiquitinating enzymes and in the majority of cases these enzymes exhibit specificity in sustaining either pro-tumorigenic or tumour repressive responses.

View Article and Find Full Text PDF

The amplitude of transforming growth factor-β (TGF-β) signal is tightly regulated to ensure appropriate physiological responses. As part of negative feedback loop SMAD7, a direct transcriptional target of downstream TGF-β signaling acts as a scaffold to recruit the E3 ligase SMURF2 to target the TGF-β receptor complex for ubiquitin-mediated degradation. Here, we identify the deubiquitinating enzyme USP26 as a novel integral component of this negative feedback loop.

View Article and Find Full Text PDF
Article Synopsis
  • Ubiquitin modification plays a crucial role in regulating the TGF-β signaling pathway through mechanisms involving feedback loops and degradation processes.
  • The E3 ligase SMURF2 tags the TGF-β receptor complex for degradation, while recent findings have identified special enzymes called deubiquitinating enzymes (DUBs) that can stabilize this receptor.
  • The study highlights USP15 as a key DUB that not only stabilizes the TGF-β receptor by deubiquitinating it but also enhances TGF-β signaling by modifying SMURF2, indicating a complex interplay between these proteins in the regulation of TGF-β pathways.
View Article and Find Full Text PDF